Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mirko Acquati"'
Autor:
Daniele Santini, Saverio Cinieri, Donatello Gasparro, Roberto Bordonaro, Pamela Francesca Guglielmini, Vincenzo Emanuele Chiuri, Rolando M D'Angelillo, Giovanni Luca Ceresoli, Daniele Fagnani, Mirko Acquati, Manlio Mencoboni, Gaetano Lanzetta, Donata Sartori, Paolo Carlini, Fabiana Panebianco, Patrizia Beccaglia, Giuseppe Procopio
Publikováno v:
Journal of Bone Oncology, Vol 26, Iss , Pp 100341- (2021)
Background: Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration-resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this pr
Externí odkaz:
https://doaj.org/article/81c32569eace4c8faac43a497b6f1d4c
Autor:
Fabiana Panebianco, Donatello Gasparro, Paolo Carlini, Giovanni Luca Ceresoli, Rolando Maria D'Angelillo, Saverio Cinieri, Giuseppe Procopio, Daniele Santini, Daniele Fagnani, Pamela Guglielmini, Patrizia Beccaglia, Roberto Bordonaro, Gaetano Lanzetta, Manlio Mencoboni, Vincenzo Emanuele Chiuri, Donata Sartori, Mirko Acquati
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 26, Iss, Pp 100341-(2021)
Journal of Bone Oncology, Vol 26, Iss, Pp 100341-(2021)
Highlights • Bone remodeling is disrupted in metastatic disease, affecting > 70% of mCRPC men. • In metastatic disease, abnormal levels of specific BTMs are released. • We prospectively measured four BTMs markers in chemotherapy-naïve mCRPC me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a8ec0a57936f350d221b062fd34b9c6
https://pubmed.ncbi.nlm.nih.gov/33425672
https://pubmed.ncbi.nlm.nih.gov/33425672
Autor:
Paola Queirolo, Mirko Acquati
Publikováno v:
Cancer Treatment Reviews. 32:524-531
In the last decade the incidence of melanoma has been rising. Despite this, survival remains substantially constant because early diagnosis of thin lesions has increased. By contrast, metastatic melanoma continues to have a poor prognosis and it stil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6b127bf32c74b7006e8c65cd3b493e0
https://doi.org/10.1016/j.ctrv.2006.07.009
https://doi.org/10.1016/j.ctrv.2006.07.009
Autor:
John M. Kirkwood, Andrea Rocca, Mirko Acquati, Alessandro Testori, Alexander M.M. Eggermont, Paola Queirolo
Publikováno v:
Melanoma Research, 15(5), 319-324. Lippincott Williams & Wilkins
The incidence of melanoma has increased continuously during the last decade. Surgery is the mainstay of therapy but, for patients with thick lesions or regional metastatic lymph nodes, there is a high risk of relapse. For this group of patients, ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4848f7e0ef926eb570ee408877516f2d
https://doi.org/10.1097/00008390-200510000-00001
https://doi.org/10.1097/00008390-200510000-00001
Autor:
Mirko Acquati, Stefania Vecchio, Alessio Signori, Domenico Franco Merlo, Paola Queirolo, Francesco Spagnolo, Paolo Pronzato
The management of melanoma brain metastases (MBM) includes different therapeutic modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of treatments, survival remains poor, exceeding 1 year only in patients with solitary meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90830b751f6ac0396eb336f96953de31
https://hdl.handle.net/11567/810681
https://hdl.handle.net/11567/810681
Autor:
Mirko Acquati, Paola Queirolo
Publikováno v:
Melanoma research. 15(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b97c8c94ae93d46f35e0dd87f59ea163
https://pubmed.ncbi.nlm.nih.gov/16179877
https://pubmed.ncbi.nlm.nih.gov/16179877
Autor:
Silvana, Chiara, Maria Teresa, Nobile, Laura, Tomasello, Mirko, Acquati, Paola, Taveggia, Carmelina, Murolo, Pierluigi, Percivale, Riccardo, Rosso
Publikováno v:
Anticancer research. 25(2B)
Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical data suggest a remarkable synergistic activity. Phase I studies demonstrated that single-agent full dose of both drugs can be administered with moderate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0874ad18946e993c6419889e76ba4c4e
https://pubmed.ncbi.nlm.nih.gov/15865096
https://pubmed.ncbi.nlm.nih.gov/15865096